![]() ![]() Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al.Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Increasing hospitalizations due to angioedema in the United States. Pattern of hospitalizations for angioedema in New York between 19. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andrén L, Wiholm BE. Papers of particular interest, published recently, have been highlighted as: Their use should be avoided in high-risk individuals and early diagnosis, tracheal intubation in cases of airway compromise, and absolute avoidance of re-challenge are important. ConclusionĪCE-I are frequently used therapeutic agents that are associated with angioedema. Patients with a history of ACE-I-induced angioedema should not be re-challenged with this class of agents, as there is a relatively high risk of recurrence. Treatment modalities include antihistamines, steroids, and epinephrine, as well as endotracheal intubation in cases of airway compromise. The pathophysiology of ACE-I-induced angioedema involves inhibition of bradykinin and substance P degradation by ACE (kininase II) leading to vasodilator and plasma extravasation. Angioedema occurs more frequently in African Americans, smokers, women, older individuals, and those with a history of drug rash, seasonal allergies, and use of immunosuppressive therapy. The widespread use of ACE-I resulted in one third of all emergency department visits for angioedema. Recent FindingsĪngiotensin-converting enzyme inhibitors (ACE-I), a medication class used by an estimated 40 million people worldwide, are associated with angioedema that occurs with incidence ranging from 0.1 to 0.7%. This study aims to examine current knowledge on the occurrence, pathophysiology, and treatment of angioedema among patients who receive angiotensin-converting enzyme inhibitors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |